Research Papers:

Improved method for prioritization of disease associated lncRNAs based on ceRNA theory and functional genomics data

Peng Wang, Qiuyan Guo, Yue Gao, Hui Zhi, Yan Zhang, Yue Liu, Jizhou Zhang, Ming Yue, Maoni Guo, Shangwei Ning, Guangmei Zhang and Xia Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:4642-4655. https://doi.org/10.18632/oncotarget.13964

Metrics: PDF 2263 views  |   HTML 3082 views  |   ?  


Peng Wang1,*, Qiuyan Guo2,*, Yue Gao1,*, Hui Zhi1, Yan Zhang1, Yue Liu1, Jizhou Zhang1, Ming Yue1, Maoni Guo1, Shangwei Ning1,3, Guangmei Zhang2, Xia Li1,3

1College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China

2The First Affiliated Hospital, Harbin Medical University, Harbin, China

3Key Laboratory of Cardiovascular Medicine Research, Harbin Medical University, Ministry of Education, China

*These authors contributed equally to this work

Correspondence to:

Xia Li, email: [email protected]

Guangmei Zhang, email: [email protected]

Shangwei Ning, email: [email protected]

Keywords: long non-coding RNA, competing endogenous RNA, functional genomics, prognostic biomarker

Received: August 20, 2016     Accepted: December 07, 2016     Published: December 15, 2016


Although several computational models that predict disease-associated lncRNAs (long non-coding RNAs) exist, only a limited number of disease-associated lncRNAs are known. In this study, we mapped lncRNAs to their functional genomics context using competing endogenous RNAs (ceRNAs) theory. Based on the criteria that similar lncRNAs are likely involved in similar diseases, we proposed a disease lncRNA prioritization method, DisLncPri, to identify novel disease-lncRNA associations. Using a leave-one-out cross validation (LOOCV) strategy, DisLncPri achieved reliable area under curve (AUC) values of 0.89 and 0.87 for the LncRNADisease and Lnc2Cancer datasets that further improved to 0.90 and 0.89 by integrating a multiple rank fusion strategy. We found that DisLncPri had the highest rank enrichment score and AUC value in comparison to several other methods for case studies of alzheimer's disease, ovarian cancer, pancreatic cancer and gastric cancer. Several novel lncRNAs in the top ranks of these diseases were found to be newly verified by relevant databases or reported in recent studies. Prioritization of lncRNAs from a microarray (GSE53622) of oesophageal cancer patients highlighted ENSG00000226029 (top 2), a previously unidentified lncRNA as a potential prognostic biomarker. Our analysis thus indicates that DisLncPri is an excellent tool for identifying lncRNAs that could be novel biomarkers and therapeutic targets in a variety of human diseases.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13964